Representing Kansas bioscience companies and research institutions
Home About KansasBio Membership Center Bioscience News Contact KansasBio
Information Resources Education & Training Networking & Collaboration Business & Investment

 

Up-to-the minute latest news in the biotechnology sector and from biotech companies in Kansas and around the world

  KansasBio photos  

Search:
 

Veloxis Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference

 

HORSHOLM, Denmark, Feb. 29, 2012 /PRNewswire/ -- Edward Koval, senior vice president, business development, of Veloxis Pharmaceuticals A/S, will present at the Cowen and Company 32nd Annual Health Care Conference at 2:10 p.m. EST, Monday, March 5, at the Boston Marriott Copley Place in Boston. Mr. Koval will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro™, Veloxis' candidate to prevent organ transplant rejection. 

About Veloxis Pharmaceuticals A/S

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development.

For further information, please visit www.veloxis.com.

For U.S. investor and media contacts:

John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
(732) 321-3208
jdw@veloxis.com

SOURCE Veloxis Pharmaceuticals A/S

Back to top

RELATED LINKS
http://www.veloxis.com

 



Kansas Bioscience Association

© 2004 Kansas Bioscience Organization (KansasBio). All rights reserved.